Search
forLearn
5 / 801 resultslearn HT-B
learn PTT-6®
learn microbiota modulator
learn NMN
Research
5 / 1000+ results
research Development of modified montmorillonite-bacterial cellulose nanocomposites as a novel substitute for burn skin and tissue regeneration
New nanocomposites with copper show promise for healing burn wounds and regenerating skin.
research Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of β-catenin in mice
Wnt signaling is vital for cell growth, development, and cancer research.
research Polycystic Ovarian Syndrome and Obstructive Sleep Apnea
Women with PCOS are much more likely to have sleep problems and should be checked for them.
research Identification of a new plant extract for androgenic alopecia treatment using a non-radioactive human hair dermal papilla cell-based assay
A new plant extract from Avicennia marina could potentially be used to treat common hair loss.
research EARLY CARDIAC DAMAGE FOLLOWING SINGLE AND COMBINED EXPOSURE TO LITHIUM CARBONATE AND LEAD ACETATE IN RATS: A TOXICOLOGICAL PERSPECTIVE
Lithium carbonate and lead acetate together harm the heart more than individually.
Community Join
5 / 1000+ resultscommunity PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community How much do we know about PTD-DBM?
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community Wrap it up everyone. CB-03-01 is another failed treatment
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.